Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 7:15 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 361–384 of 791 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endometrium Cancer Clear all
Completed Not applicable Interventional Results available

FitEx for Endometrial Cancer Survivors: Initial Efficacy

NCT05737745
View directory record Official record
Conditions
Endometrial Cancer, Obesity, Sedentary Behavior, Quality of Life, Survivorship
Interventions
Self-monitoring, Group-dynamics, Weekly virtual sessions- Standard, Newsletters- Standard, Newsletters- Yoga, Weekly virtual sessions- Yoga
Behavioral
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated May 9, 2025 · Synced Oct 23, 2026, 7:15 PM EDT
Active, not recruiting Phase 3 Interventional

Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)

NCT04634877
View directory record Official record
Conditions
Endometrial Neoplasms
Interventions
Pembrolizumab, Carboplatin, Paclitaxel, Placebo for pembrolizumab, Docetaxel, Cisplatin, External Beam Radiotherapy (EBRT), Cisplatin (as radiosensitizer), Brachytherapy
Biological · Drug · Radiation
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
990 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
29
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ET-743 (Trabectedin) in Patients With Persistent or Recurrent Endometrial Carcinoma

NCT00050440
View directory record Official record
Conditions
Endometrial Neoplasms, Uterine Neoplasms, Genital Neoplasms, Female Urogenital Neoplasms
Interventions
Trabectedin, Dexamethasone
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2004
U.S. locations
8
States / cities
Los Angeles, California • Miami, Florida • Lexington, Kentucky + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2013 · Synced Oct 23, 2026, 7:15 PM EDT
Recruiting Phase 3 Interventional

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

NCT06340568
View directory record Official record
Conditions
Endometrial Cancer
Interventions
BNT323/DB-1303, Doxorubicin, Paclitaxel, Docetaxel
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older · Female only
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
22
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Biomarkers for Gynecologic Cancer

NCT02178462
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Benign Gynecological Disease
Interventions
Not listed
Lead sponsor
Ajinomoto Co., Inc.
Industry
Eligibility
20 Years to 80 Years · Female only
Enrollment
153 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2018
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jan 31, 2018 · Synced Oct 23, 2026, 7:15 PM EDT
Terminated Not applicable Interventional

Feasibility Study: Accuracy of Biomarker in Detection of Endometrial Cancer

NCT00471120
View directory record Official record
Conditions
Uterine Cancer, Endometrial Cancer
Interventions
P2x7 assay
Other
Lead sponsor
Dick Domanik
Industry
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
5
States / cities
Little Rock, Arkansas • Cleveland, Ohio • Dallas, Texas + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2015 · Synced Oct 23, 2026, 7:15 PM EDT
Terminated No phase listed Observational

A Biomarker Screening Protocol for Participants With Solid Tumors

NCT05891197
View directory record Official record
Conditions
Triple Negative Breast Cancer, Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic, Non-Small Cell Carcinoma of Lung, TNM Stage 4, Advanced Breast Cancer, Advanced Lung Carcinoma, NSCLC, NSCLC, Recurrent, NSCLC Stage IV, Relapsed Cancer, Relapse/Recurrence, Recurrent Breast Cancer, Recurrent NSCLC, Platinum-resistant Ovarian Cancer, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Endometrial Cancer, Endometrioid Tumor, High Grade Serous Carcinoma, Ovarian Epithelial Cancer
Interventions
Not listed
Lead sponsor
Lyell Immunopharma, Inc.
Industry
Eligibility
18 Years to 99 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Rocky Mount, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Not applicable Interventional

Gentle Yoga and Dietary Counseling in Improving Physical Function and Quality of Life in Stage I-II Endometrial Cancer Survivors

NCT02465541
View directory record Official record
Conditions
Obesity, Endometrial Carcinoma
Interventions
Gentle yoga therapy, counseling intervention, educational intervention, quality-of-life assessment, questionnaire administration
Procedure · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2022
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 23, 2026, 7:15 PM EDT
Active, not recruiting Not applicable Interventional

Genetic Testing in African Americans

NCT05591131
View directory record Official record
Conditions
Ovarian Cancer, Endometrial Cancer, Peritoneal Cancer
Interventions
genetic testing, Survey Administration
Other
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2025 · Synced Oct 23, 2026, 7:15 PM EDT
Not listed Phase 1 Interventional

A Study of SBT6050 Alone and in Combination With PD-1 Inhibitors in Subjects With Advanced HER2 Expressing Solid Tumors

NCT04460456
View directory record Official record
Conditions
HER2 Positive Solid Tumors
Interventions
SBT6050, pembrolizumab, Cemiplimab
Drug
Lead sponsor
Silverback Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Boston, Massachusetts • Durham, North Carolina • Pittsburgh, Pennsylvania + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 23, 2026, 7:15 PM EDT
Not listed Phase 2 Interventional Accepts healthy volunteers

Chemotherapy With Whole Body Hyperthermia to Treat Resistant Breast, Endometrial, Cervical and Ovarian Cancers

NCT00178802
View directory record Official record
Conditions
Breast Neoplasms, Endometrial Neoplasms, Cervix Neoplasms, Ovarian Neoplasms
Interventions
thermochemotherapy (with 5-fluorouracil/interferon-a/liposomal doxorubicin)
Other
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
Female only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1996 – 2010
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 23, 2010 · Synced Oct 23, 2026, 7:15 PM EDT
Recruiting No phase listed Observational

Development of a Shared Decision Tool to Facilitate Uptake of the Levonorgestrel-releasing Intrauterine System for the Primary Prevention of Endometrial Cancer

NCT07382583
View directory record Official record
Conditions
Levonorgestrel, Intrauterine Systems, Prevention, Endometrial Cancer
Interventions
Survey using a questionnaire
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional

HPV Vaccine, Imiquimod, and Metformin Combination Trial

NCT06686043
View directory record Official record
Conditions
Cervical Carcinoma, Vaginal Carcinoma, Vulvar Carcinoma, HPV (Human Papillomavirus)-Associated Carcinoma
Interventions
HPV vaccine, Imiquimod, and metformin combination therapy
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years to 64 Years · Female only
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 23, 2026, 7:15 PM EDT
Recruiting Phase 2 Interventional

PROton Therapy for Post Surgical Treatment of GYNecologic Cancer

NCT05758688
View directory record Official record
Conditions
Cervical Cancer, Uterine Cancer, Endometrial Cancer
Interventions
Whole Pelvis (WP) Pencil Beam Scanning Proton Radiation (PBS PRT)
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Voorhees Township, New Jersey • Lancaster, Pennsylvania • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Uterine Fibroids With the Selective Progesterone Receptor Modulator CDB-2914

NCT00290251
View directory record Official record
Conditions
Leiomyoma
Interventions
ulipristal acetate 20 mg, ulipristal acetate 10 mg, placebo
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
25 Years to 50 Years · Female only
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional

EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

NCT00107445
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions
EF5
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 16, 2013 · Synced Oct 23, 2026, 7:15 PM EDT
Active, not recruiting No phase listed Observational

Weight Loss Management in Endometrial Cancer Survivors

NCT06877572
View directory record Official record
Conditions
Endometrial Cancer Survivors, Weight Management, Early Stage Endometrial Cancer
Interventions
Weight loss with pharmacotherapy, Weight loss without pharmacotherapy
Behavioral
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Not applicable Interventional

Caloric Restriction Before Surgery in Treating Patients With Endometrial, Prostate, or Breast Cancer

NCT02983279
View directory record Official record
Conditions
Breast Carcinoma, Endometrial Carcinoma, Prostate Carcinosarcoma
Interventions
Dietary Intervention, Counseling, Therapeutic
Dietary Supplement · Other · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in Uterine Serous Cancer

NCT01367002
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Carboplatin/Paclitaxel, Trastuzumab
Drug
Lead sponsor
Yale University
Other
Eligibility
Female only
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2022
U.S. locations
20
States / cities
Phoenix, Arizona • Tucson, Arizona • Concord, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 17, 2023 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

FitEx for Endometrial Cancer Survivors

NCT05233059
View directory record Official record
Conditions
Quality of Life, Cancer of Endometrium, Behavior, Health, Self Efficacy
Interventions
FitEx, Weekly Yoga Sessions, Weekly Movement Sessions
Behavioral
Lead sponsor
Carilion Clinic
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Roanoke, Virginia
Source: ClinicalTrials.gov public record
Updated Feb 8, 2023 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Not applicable Interventional

TREC Lifestyle Beyond Cancer Study in Endometrial Cancer Survivors

NCT02466061
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Telemedicine Weight Management plus Wi-Fi Scale (Arm A), Text for Diet (Text4Diet) Group (Arm B), Enhanced Usual Care Group (Arm C)
Behavioral
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
Boston, Massachusetts • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 2, 2016 · Synced Oct 23, 2026, 7:15 PM EDT
Not listed No phase listed Observational

Lynch Syndrome Can be Diagnosed Just From Somatic Mismatch Repair Mutation

NCT04516083
View directory record Official record
Conditions
Cancer Gene Mutation, Lynch Syndrome, Endometrial Cancer, Somatic Mutation
Interventions
Mismatch repair instability somatic and germline testing
Diagnostic Test
Lead sponsor
RWJ Barnabas Health at Jersey City Medical Center
Other
Eligibility
Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Aug 18, 2020 · Synced Oct 23, 2026, 7:15 PM EDT
Recruiting Phase 1Phase 2 Interventional

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

NCT04851119
View directory record Official record
Conditions
Colorectal Carcinoma, Endometrial Carcinoma, Melanoma, Neuroblastoma, Ovarian Carcinoma, Pancreatic Ductal Adenocarcinoma, Recurrent Desmoid Fibromatosis, Recurrent Ewing Sarcoma, Recurrent Hepatoblastoma, Recurrent Hepatocellular Carcinoma, Recurrent Malignant Solid Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Osteosarcoma, Refractory Desmoid Fibromatosis, Refractory Ewing Sarcoma, Refractory Hepatoblastoma, Refractory Hepatocellular Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Osteosarcoma, Solid Pseudopapillary Neoplasm of the Pancreas, Wilms Tumor
Interventions
Biospecimen Collection, Dual X-ray Absorptiometry, Tegavivint, X-Ray Imaging
Procedure · Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
12 Months to 30 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
21
States / cities
Birmingham, Alabama • Los Angeles, California • Orange, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 23, 2026, 7:15 PM EDT
Completed Phase 2 Interventional Results available

Papillary Serous Carcinoma of the Endometrium

NCT00515073
View directory record Official record
Conditions
Endometrial Cancer
Interventions
Paclitaxel, Pelvic Radiation, Dexamethasone, Cimetidine, Diphenhydramine
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2013
U.S. locations
2
States / cities
Orlando, Florida • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 3, 2014 · Synced Oct 23, 2026, 7:15 PM EDT